Hypertension and liver disease

Current Hypertension Reports

Volumn 6, Issue 6, 2004, Pages 453-461

  Henriksen, Jens H ^a   Møoller, Søoren ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ALDOSTERONE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCITONIN GENE RELATED PEPTIDE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; HYPERTENSIVE AGENT; NITRIC OXIDE; ORNIPRESSIN; PRAZOSIN; RENIN; TERLIPRESSIN; URODILATIN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR;

ADRENERGIC SYSTEM; ARTERIAL PRESSURE; ARTERY COMPLIANCE; BLOOD PRESSURE REGULATION; BLOOD VOLUME; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FLUID RETENTION; HEART DISEASE; HEART OUTPUT; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER DISEASE; NEUROENDOCRINE SYSTEM; PLASMA RENIN ACTIVITY; PORTAL HYPERTENSION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR DISEASE; REVIEW; SPLANCHNIC BLOOD FLOW; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION; VASOPRESSIN RELEASE;

EID: 10044268385     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-004-0041-5     Document Type: Review

References (50)

1. Cohen L, Guillevin L, Meyrier A, et al.: Malignant arterial hypertension in periarteritis nodosa. Incidence, clinicobiologic parameters and prognosis based on series of 165 cases. Arch Mal Coeur Vaiss 1986, 79:773-778.
2. Klatsky A, Friedman GD, Siegelaub AB, Gerard MJ: Alcohol consumption and blood pressure. Kaiser-Permanente Multiphasic Health Examination Data. N Engl J Med 1977, 296:1194-1200.
3. Ascherio A, Rimm EB, Giovannucci EL, et al.: A prospective study of nutritional factors and hypertension among US men Circulation 1992, 86:1475-1484.
4. Potter JF, Beevers DG: Pressor effect of alcohol in hypertension. Lancet 1984, i:119-120.
5. Arroyo V, Gines P, Jimenez W, Rodes J: Ascites, renal failure, and electrolyte disorders in cirrhosis. Pathogenesis, diagnosis, and treatment. In Oxford Textbook of Clinical Hepatology. Edited by McIntyre N, Benhamou JP, Bircher J, et al. Oxford: Oxford University Press; 1991:427-470.
6. Schrier RW, Arroyo V, Bernardi M, et al.: Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 5: 151-1157.
7. Groszmann RJ: Vasodilatation and hyperdynamic circulatory state in chronic liver disease. In Portal Hypertension. Pathophysiology and Treatment. Edited by Bosch J, Groszmann RJ. Oxford: Blackwell; 1994:17-26.
8. Henriksen JH, Bendtsen F, Sørensen TIA, et al.: Reduced central blood volume in cirrhosis. Gastroenterology 1989, 97:1506-1513.
9. Henriksen JH, Fuglsang S, Bendtsen F, et al.: Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index. Am J Physiol Gastrointest Liver Physiol 2001, 280:G584-G594.
10. Møller S, Henriksen JH, Bendtsen F: Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. Am J Physiol Gastrointest Liver Physiol 2003, 284:G970-G979.
11. Krousel-Wood MA, Muntner P, He J, Whelton PK: Primary prevention of essential hypertension. Med Clin North Am 2004, 88:223-238.
12. Andersen UO, Henriksen JH, Jensen G: Sources of measurement variation in blood pressure in large-scale epidemiological surveys with follow-up. The Copenhagen City Heart Study Group. Blood Press 2002, 11:357-365.
13. Ekataksin W, Kaneda K: Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999, 19:359-382.
14. Wiest R, Groszmann RJ: The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002, 35:478-491.
15. Martin PY, Gines P, Schrier RW: Mechanisms of disease: nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998, 339: 33-541.
16. Ring-Larsen H, Henriksen JH: Pathogenesis of ascites formation and hepatorenal syndrome: humoral and hemodynamic factors. Semin Liver Dis 1986, 6:341-352.
17. Møller S, Bendtsen F, Henriksen JH: Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001, 61:421-430.
18. Møller S, Bendtsen F, Henriksen JH: Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. Can J Gastroenterol 2001, 15:94-106.
19. Jimenez W, Arroyo: Origins of cardiac dysfunction in cirrhosis. Gut 2003, 52:1392-1394.
20. Liu H, Song D, Lee SS: Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002, 26:842-847.
21. Gentilini P, Romanelli RG, Laffi G, et al.: Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture. J Hepatol 1999, 30:632-638.
22. Lopez C, Jimenez W, Arroyo V, et al.: Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis. Hepatology 1991, 13: 85-589.
23. Loyke HF: Reduction of hypertension after liver disease Arch Intern Med 1962, 110:45-49.
24. Spatt SD, Rosenblatt P: The incidence of hypertension in portal cirrhosis: a study of 80 necropsied cases of portal cirrhosis. Ann Int Med 1949, 31:479-483.
25. Loyke HF, Cutarelli R: An evaluation of hypertension and liver disease in an alcoholic service. Am J Med Sci 1960, 240:346-351.
26. Schrier RW: Renin-angiotensin in preascitic cirrhosis: evidence for primary peripheral arterial vasodilution. Gastroenterology 1998, 115:489-91.
27. Møller S, Wiinberg N, Henriksen JH: Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology 1995, 22:88-95.
28. Loyke HF: The relationship of cirrhosis of the liver to hypertension: a study of 504 cases of cirrhosis of the liver. Am J Med Sci 1955, 230:627-632.
29. Veglio F, Pinna G, Melchio R, et al.: Hormonal aspects of the relation of liver cirrhosis to essential hypertension. Clin Exp Hypertens 1992, 14:889-903.
30. Raaschou F: Blood pressure and heart weight in chronic hepatitis: Does the liver play a role in the development of essential hypertension? Nord Med 1949, 46:1791-1795.
31. Henriksen JH, Møller S, Schifter S, et al.: High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems. Gut 2001, 49:112-118.
32. Brinch K, Møller S, Bendtsen F, et al.: Plasma volume expansion by albumin in cirrhosis: relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003, 39:24-31.
33. Møller S, Gülberg V, Becker U, et al.: Elevated arterial compliance in patients with cirrhosis is not related to arterial endothelin-1. Scand J Gastroenterol 2002, 37:1064-1069.
34. Henriksen JH, Gülberg V, Gerbes AL, et al.: Increased arterial compliance in cirrhosis is related to decreased arterial C-type natriuretic peptide, but not to atrial natriuretic peptide. Scand J Gastroenterol 2003, 38:559-564.
35. Møller S, Henriksen JH: Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002, 87:9-15.
36. Møller S, Hansen EF, Becker U, et al.: Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000, 20:51-59.
37. D'Amico G: The role of vasoactive drugs in the treatment of oesophageal varices. Expert Opin Pharmacother 2004, 5: 49-360.
38. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F: Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J Hepatol 2001, 35: 05-612.
39. Hadengue A, Moreau R, Gaudin C, et al.: Total effective vascular compliance in patients with cirrhosis: a study of the response to acute blood volume expansion. Hepatology 1992, 15:809-815.
40. Andreu V, Perello A, Moitinho E, et al.: Total effective vascular compliance in patients with cirrhosis: effects of propranolol. J Hepatol 2002, 36:356-361.
41. Møller S, Bendtsen F, Henriksen JH: Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995, 109:1917-1925.
42. Henriksen JH, Fuglsang S, Bendtsen F, et al.: Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002, 36:513-520.
43. Henriksen JH, Gøtze JP, Fuglsang S, et al.: Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003, 52:1511-1517.
44. Gines P, Guevara M, Arroyo V, Rodes J: Hepatorenal syndrome. Lancet 2003, 362:1819-1827.
45. Moore K: Endothelin and vascular function in liver disease Gut 2004, 53:159-161.
46. Møller S, Gülberg V, Henriksen JH, et al.: Endothelin-1 and endothelin-3 in cirrhosis: relations to systemic and splanchnic haemodynamics. J Hepatol 1995, 23:135-144.
47. Mohammed R, Forsey PR, Davies MK, Neuberger JM: Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996, 23: 128-1134.
48. Vallance P, Moncada S: Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991, 337: 76-778.
49. Henriksen JH, Ring-Larsen H: Renal effects of drugs used in the treatment of portal hypertension. Hepatology 1993, 18: 88-695.
50. Schwartz DT: The relation of cirrhosis of the liver to renal hypertension: a review of 639 autopsied cases. Ann Intern Med 1967, 66:862-869.